ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.738,81
-0,72%
S&P 500
5.297,10
-0,21%
Dow Jones
39.869,38
-0,10%
Euro vs US Dollar
1,08673
-0,20%
Bitcoin
65.353,93
0,18%
Registration Strip Icon for charts Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Kiniksa Pharmaceuticals Ltd (KNSA)

  7. Kiniksa Pharmaceuticals Ltd (KNSA) News

KNSA

Kiniksa Pharmaceuticals (KNSA)

Kiniksa Pharmaceuticals Ltd
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:KNSA
DatumZeitQuelleÜberschriftSymbolFirma
07/05/202422h01GlobeNewswire Inc.Kiniksa Pharmaceuticals to Present at Bank of America Securities 2024 Health Care ConferenceNASDAQ:KNSAKiniksa Pharmaceuticals Ltd
23/04/202413h30GlobeNewswire Inc.Kiniksa Pharmaceuticals Reports First Quarter 2024 Financial Results and Recent Portfolio ExecutionNASDAQ:KNSAKiniksa Pharmaceuticals Ltd
16/04/202422h01GlobeNewswire Inc.Kiniksa Pharmaceuticals to Report First Quarter 2024 Financial Results on April 23, 2024NASDAQ:KNSAKiniksa Pharmaceuticals Ltd
02/04/202413h30GlobeNewswire Inc.Kiniksa Pharmaceuticals Announces Development Indication for AbiprubartNASDAQ:KNSAKiniksa Pharmaceuticals Ltd
05/03/202422h34Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KNSAKiniksa Pharmaceuticals Ltd
05/03/202422h31Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KNSAKiniksa Pharmaceuticals Ltd
01/03/202423h29Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:KNSAKiniksa Pharmaceuticals Ltd
29/02/202422h26Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KNSAKiniksa Pharmaceuticals Ltd
28/02/202413h35Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KNSAKiniksa Pharmaceuticals Ltd
28/02/202413h30GlobeNewswire Inc.Kiniksa Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Portfolio ExecutionNASDAQ:KNSAKiniksa Pharmaceuticals Ltd
27/02/202423h06Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:KNSAKiniksa Pharmaceuticals Ltd
21/02/202422h01GlobeNewswire Inc.Kiniksa Pharmaceuticals to Report Fourth Quarter and Full-Year 2023 Financial Results on February 28, 2024NASDAQ:KNSAKiniksa Pharmaceuticals Ltd
14/02/202422h39Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:KNSAKiniksa Pharmaceuticals Ltd
14/02/202421h46Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:KNSAKiniksa Pharmaceuticals Ltd
04/01/202422h30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KNSAKiniksa Pharmaceuticals Ltd
04/01/202413h37Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KNSAKiniksa Pharmaceuticals Ltd
04/01/202413h30GlobeNewswire Inc.Kiniksa Pharmaceuticals Provides Corporate UpdateNASDAQ:KNSAKiniksa Pharmaceuticals Ltd
03/01/202422h55Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:KNSAKiniksa Pharmaceuticals Ltd
02/01/202422h01GlobeNewswire Inc.Kiniksa Pharmaceuticals to Present at 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:KNSAKiniksa Pharmaceuticals Ltd
11/12/202322h20Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KNSAKiniksa Pharmaceuticals Ltd
07/12/202322h46Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:KNSAKiniksa Pharmaceuticals Ltd
02/11/202321h15Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:KNSAKiniksa Pharmaceuticals Ltd
31/10/202312h35Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KNSAKiniksa Pharmaceuticals Ltd
31/10/202312h30GlobeNewswire Inc.Kiniksa Pharmaceuticals Reports Third Quarter 2023 Financial Results and Recent Portfolio ExecutionNASDAQ:KNSAKiniksa Pharmaceuticals Ltd
24/10/202322h01GlobeNewswire Inc.Kiniksa Pharmaceuticals to Report Third Quarter 2023 Financial Results on October 31, 2023NASDAQ:KNSAKiniksa Pharmaceuticals Ltd
07/09/202301h07Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KNSAKiniksa Pharmaceuticals Ltd
07/09/202301h06Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KNSAKiniksa Pharmaceuticals Ltd
07/09/202301h04Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KNSAKiniksa Pharmaceuticals Ltd
07/09/202301h03Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KNSAKiniksa Pharmaceuticals Ltd
05/09/202323h26Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:KNSAKiniksa Pharmaceuticals Ltd
 Showing the most relevant articles for your search:NASDAQ:KNSA

Kürzlich von Ihnen besucht

USOTC
RHHBY
Roche (QX)
DBI
SDXP
SDAX
NYSE
KO
Coca Cola
NASDAQ
NVDA
NVIDIA
TG
D7G
Nel ASA
NASDAQ
AAPL
Apple
AMEX
XLV
Health Care Select Sector
COIN
ETHUSD
Ethereum
TG
DBK
Deutsche Bank
TG
432
Arbor Metals
FX
EURUSD
Euro vs US Dollar
CCOM
SILVER
SILVER
NASDAQ
TSLA
Tesla
NYSE
XOM
Exxon Mobil
TG
TUI1
Tui
Delayed Upgrade Clock
ADVFN Logo

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten